The EPS miss is largely irrelevant for a pre-revenue clinical-stage biotech — the stock will trade on pipeline catalysts. Key events to watch: opakalim RISE3 topline in 2H 2026 (potentially transformative for epilepsy), BHV-1400 IgAN pivotal study initiation, and taldefgrobep alfa obesity data. The $270.5M cash position provides runway through these catalysts but burn rate warrants monitoring.
Price Chart
Executive Summary
Biohaven reported Q2 2026 financial results with a GAAP net loss of $137.3M ($0.91/share), significantly wider than the consensus estimate of $-0.61/share, representing a 48.9% miss. The company highlighted major pipeline progress including initiation of a pivotal Phase 3 trial for BHV-1300 in Graves' disease and strong clinical data across its extracellular degrader and epilepsy platforms, with multiple key readouts on track for 2H 2026. The EPS miss is driven by pre-revenue clinical-stage operating losses and non-cash derivative charges, while the pipeline catalysts represent the primary value drivers for this clinical-stage biotech.
Key Financial Metrics
Key Facts
- GAAP net loss of $137.3M ($0.91/share) vs consensus $-0.61 — a 48.9% miss
- Cash position of $270.5M as of June 30, 2026, down from $351.8M at March 31, 2026
- Initiated pivotal Phase 3 study for BHV-1300 (MoDE degrader) in Graves' disease
- BHV-1400 (TRAP degrader) pivotal study in IgAN expected to initiate in 2H 2026
- Topline results from Phase 2/3 RISE3 trial of opakalim in focal epilepsy on track for 2H 2026
- Phase 2 obesity study of taldefgrobep alfa enrollment complete; topline data expected 2H 2026
- R&D expenses decreased to $100.8M from $184.4M YoY due to strategic reprioritization
- First-in-human dosing commenced for oral PKM2 modulator BHV-8100
Financial Impact
GAAP net loss of $137.3M for Q2 2026, compared to $198.1M in Q2 2025. Cash burn of ~$81.3M from Q1 to Q2 2026. EPS miss of 48.9% vs consensus.
Risk Factors
- Clinical trial failure risk for opakalim (pivotal RISE3 readout) and degrader platforms
- Cash burn of ~$81M per quarter implies ~3.3 quarters of runway at current spend
- EPS miss of 48.9% vs consensus may create negative sentiment momentum
- Notes payable increased to $259.5M from $238.9M, adding leverage risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000067 |
| Document: bhvn-20260810.htm | 0001935979-26-000067 |
| Document: 0001935979-26-000067-index-headers.html | 0001935979-26-000067 |
| Document: 0001935979-26-000067-index.html | 0001935979-26-000067 |
| Document: 0001935979-26-000067.txt | 0001935979-26-000067 |
| 8-K Data (Synthetic) | 0001935979-26-000067 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $14.69 | awaiting T+5 | — | $13.88 (−5.51%) |
Oct 15, 2026 10d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $13.88 (+28.76%) |
Sep 9, 2026 6w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $13.88 (−8.52%) |
Aug 26, 2026 8w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $13.88 (−18.11%) |
Aug 10, 2026 10w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $13.88 (−4.21%) |
Jul 9, 2026 15w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $13.88 (−10.74%) |
May 27, 2026 21w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $13.88 (+35.55%) |
May 4, 2026 24w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $13.88 (−42.95%) |
May 4, 2026 24w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
May 4, 2026 24w ago | 8-K | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers